Zhejiang Huahai Pharmaceutical Co Ltd - Asset Resilience Ratio
Zhejiang Huahai Pharmaceutical Co Ltd (600521) has an Asset Resilience Ratio of 0.35% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2003–2025)
This chart shows how Zhejiang Huahai Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Check asset allocation strategy of Zhejiang Huahai Pharmaceutical Co Ltd to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Zhejiang Huahai Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Zhejiang Huahai Pharmaceutical Co Ltd stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥77.47 Million | 0.35% |
| Total Liquid Assets | CN¥77.47 Million | 0.35% |
Asset Resilience Insights
- Limited Liquidity: Zhejiang Huahai Pharmaceutical Co Ltd maintains only 0.35% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Zhejiang Huahai Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Zhejiang Huahai Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Almirall S.A.
MC:ALM |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 0.76% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
|
ANI Pharmaceuticals Inc
NASDAQ:ANIP |
Drug Manufacturers - Specialty & Generic | 0.63% |
|
Beijing Winsunny Pharmaceutical CO.LTD
SHG:601089 |
Drug Manufacturers - Specialty & Generic | 10.89% |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Annual Asset Resilience Ratio for Zhejiang Huahai Pharmaceutical Co Ltd (2003–2025)
The table below shows the annual Asset Resilience Ratio data for Zhejiang Huahai Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.35% | CN¥75.98 Million ≈ $11.12 Million |
CN¥21.50 Billion ≈ $3.15 Billion |
+0.05pp |
| 2024-12-31 | 0.30% | CN¥60.79 Million ≈ $8.90 Million |
CN¥20.26 Billion ≈ $2.96 Billion |
-0.20pp |
| 2023-12-31 | 0.50% | CN¥93.04 Million ≈ $13.61 Million |
CN¥18.60 Billion ≈ $2.72 Billion |
-0.29pp |
| 2022-12-31 | 0.79% | CN¥143.07 Million ≈ $20.94 Million |
CN¥18.15 Billion ≈ $2.66 Billion |
+0.78pp |
| 2021-12-31 | 0.01% | CN¥1.01 Million ≈ $148.09K |
CN¥15.47 Billion ≈ $2.26 Billion |
+0.01pp |
| 2018-12-31 | 0.00% | CN¥2.05K ≈ $299.56 |
CN¥10.37 Billion ≈ $1.52 Billion |
-3.92pp |
| 2014-12-31 | 3.92% | CN¥177.00 Million ≈ $25.90 Million |
CN¥4.51 Billion ≈ $659.96 Million |
+3.58pp |
| 2013-12-31 | 0.35% | CN¥15.60 Million ≈ $2.28 Million |
CN¥4.47 Billion ≈ $653.53 Million |
+0.18pp |
| 2012-12-31 | 0.17% | CN¥5.43 Million ≈ $794.07K |
CN¥3.22 Billion ≈ $470.69 Million |
-0.05pp |
| 2011-12-31 | 0.21% | CN¥5.53 Million ≈ $809.36K |
CN¥2.58 Billion ≈ $377.10 Million |
-10.70pp |
| 2004-12-31 | 10.91% | CN¥97.71 Million ≈ $14.30 Million |
CN¥895.55 Million ≈ $131.05 Million |
+9.36pp |
| 2003-12-31 | 1.55% | CN¥12.01 Million ≈ $1.76 Million |
CN¥774.68 Million ≈ $113.36 Million |
-- |
About Zhejiang Huahai Pharmaceutical Co Ltd
Zhejiang Huahai Pharmaceutical Co., Ltd. engaged in the research, development, production and sales of generic drugs, biological drugs, and APIs in multiple dosage forms in China and internationally. The company offers central neurological, cardiovascular, anti-viral, and other products, as well as APIs and intermediates. It also provides packaging components, such as polyethylene bottles and pol… Read more